Popular Articles

Boehringer Ingelheim And DxS Sign An Agreement For A Companion Diagnostic To Identify EGFR Mutations In Patients With Lung Cancer
DxS, a personalised medicine company, and Boehringer Ingelheim, a global group of pharmaceutical companies, headquartered in Germany, have entered into an agreement to provide a companion diagnostic test kit for Boehringer Ingelheim"s compound BIBW 2992 (Tovok™) to identify mutations of the EGFR (epidermal growth factor receptor) in patients with non small cell lung cancer. Financial terms of the agreement are not disclosed.

Regulator Says NHS Must Do More To Protect Children From Neglect And Abuse
CQC publishes national review of NHS child safeguarding
News of the day
Unjust Stigma, Lack Of Physician Training Hinder Market For IUDs, Opinion Piece Says
Intrauterine devices "seem like the perfect form of contraception: simple to use, long-lasting, reversible, hormone-free, economical," Slate columnist Kate Klonick writes. She asks, "So why are American women so late to this party? Perhaps the better question is: Why did they leave the party to begin with?"Klonick explains the benefits of IUDs, calling them a "foolproof method of birth control" and noting that they are 99% effective and "can last up to 10 years." Although IUDs can cost between $300 and $500, it is a one-time expense that is often covered by insurance, according to Klonick. She notes that although efficacy studies show that birth control pills, patches and vaginal rings can be "99% effective in a clinical setting, real-life compliancy -- like forgetting to take the pill at the same time every day -- reduces its success rate." Klonick adds that the availability of hormone-free IUDs makes them an "ideal" option for "women prone to some of the negative effects of hormonal birth control, like weight gain, mood swings, acne or high blood pressure."According to Klonick, IUDs were used by almost 10% of U.S. women taking birth control in the late 1970s but are now used by less than 2% of such women. She writes that Katharine O"Connell, a gynecologist at Columbia University who specializes in contraception, believes IUDs still carry a stigma "due to the erroneous belief that they"re highly dangerous" partly due to a number of deaths that occurred in the early 1970s tied to a specific brand of IUD known as the Dalkon Shield. Because of bad publicity surrounding the devices, "the U.S. pharmaceutical industry abandoned the research and manufacturing of IUDs in the mid-1980s, claiming the devices were no longer profitable," Klonick states. According to O"Connell, most experts now agree that the Dalkon Shield"s problems were related to its design, which made users more susceptible to infection, and a lack of testing for sexually transmitted infections before insertion.There are now two major brands of IUDs -- Mirena and ParaGard -- on the U.S. market, but physican training remains a problem, according to Klonick. She writes that studies show that premedical students are not educated regarding IUDs to the extent they are about oral contraceptive pills. O"Connell also noted that many medical schools limit classes on contraception to one lecture, which often omits IUDs. Klonick writes, "This lack of training can leave many doctors feeling uncomfortable recommending the once-controversial devices to their patients." She adds that many physicians who know how to insert and remove IUDs "still refuse to recommend it to childless patients because of the device"s checkered history." She concludes, "With Mirena advertising on television, the downturn in the economy forcing people to economize, and more women concerned about the long-term effects hormones have on their bodies, perhaps the IUD"s stigma will finally become a thing of the past" (Klonick, Slate, 7/29).
Sexual Health

Risk Factors For LRTIs In Inuit Children Identified In First Of Its Kind Study

Inuit children have the highest rate of hospital admission for Lower respiratory tract infections (LRTIs) globally, but new research shows that lowering risk factors though public health interventions and an enhanced immunization program could improve health for Inuit children and lower health care costs significantly. The first-of-its-kind case control research was conducted by Dr. Anna Banerji, a pediatric infectious disease specialist and researcher at St. Michael"s Hospital. "Infants of Inuit race were nearly four times more likely to be admitted for LRTI than mixed or non-Inuit infants," explains Dr. Banerji. "LRTI increases the risk of recurrent infections, chronic lung disease and asthma so there are many potential health complications." According to recent Statistics Canada data, the Aboriginal infant mortality rate in Nunavut is two-to-three times the Canadian average so exploring the effectiveness of immunization could have a major impact on children"s health and mortality rates. Respiratory infections are the leading cause for admission, medical evacuation and expenditure for Inuit children in the health care system and can result in serious health complications for those affected. Dr. Banerji"s key findings on the risk factors that contribute to LRTIs among Inuit children include: * Infants of mothers who smoked during pregnancy were four times more likely to be admitted for LRTI * Inuit infants were four times more likely to be admitted for LRTI than mixed or non-Inuit infants. It was not determined if this was a result of genetic factors or socio-economic factors * Overcrowded living conditions increased the risk of admission by 2.5 times * Living in a rural community without a hospital increased risk of admission by 2.7 times * Prematurity was not associated with an increased risk of admission * Infants who were not breast-fed were 3.6 times more likely to be admitted for LRTI * Infants who were custom adopted had 4.4 times the risk Dr. Banerji also conducted a cost analysis by age and location that compared the costs of administering Palivisumab prophylaxis vaccine, an antibody approved for the prevention of respiratory syncytial virus (RSV) - the most common cause of lower respiratory tract infections. The vaccine is used only for prevention and is usually a monthly injection during RSV season. The results demonstrated that by immunizing rural Inuit infants with the vaccine, the health care system could save money - up to $8,000 per admission avoided. The analysis concludes that preventative measures in infancy can both improve the health of children and result in a significant cost savings for the health-care system. Dr. Banerji"s research papers are posted online as of today (Thursday, May 21) in the Published Ahead-Of-Print section of The Pediatric Infectious Disease Journal website (www.journals.lww.com/pidj). The research by Dr. Banerji is the second major study on Indigenous children"s health recently released by the Keenan Research Centre at Li Ka Shing Knowledge Institute of St. Michael"s Hospital. Earlier this year, the centre released the Indigenous Children"s Health Report: Health Assessment in Action a project led by Dr. Janet Smylie. Tina Quelch St. Michael"s Hospital


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):